[go: up one dir, main page]

WO2006010547A2 - Matiere bioresorbable destinee a remplir les defauts osseux - Google Patents

Matiere bioresorbable destinee a remplir les defauts osseux Download PDF

Info

Publication number
WO2006010547A2
WO2006010547A2 PCT/EP2005/007908 EP2005007908W WO2006010547A2 WO 2006010547 A2 WO2006010547 A2 WO 2006010547A2 EP 2005007908 W EP2005007908 W EP 2005007908W WO 2006010547 A2 WO2006010547 A2 WO 2006010547A2
Authority
WO
WIPO (PCT)
Prior art keywords
bone
bioresorbable
bioresorbable material
material according
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007908
Other languages
German (de)
English (en)
Other versions
WO2006010547A3 (fr
Inventor
Arne Briest
Ingo Mücke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ossacur AG
Original Assignee
Ossacur AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ossacur AG filed Critical Ossacur AG
Publication of WO2006010547A2 publication Critical patent/WO2006010547A2/fr
Publication of WO2006010547A3 publication Critical patent/WO2006010547A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones

Definitions

  • the present invention relates to a bioresorbable material for filling bone defects.
  • Bone defects are to be treated in many areas of medical care, especially in orthopedics, accident surgery, maxillofacial surgery and hand surgery. Bone defects occur, for example, in fractures, in particular in debris fractures, in the clearance of cysts and tumors, in osteoporosis, in the use of hip joint prostheses, in degenerative diseases of the spine and in tooth extractions, root tip resections, partial epidural reconstructions and peridontal defects. Often it makes sense to fill up bone defects in order to replace the original Knochen ⁇ material or to stimulate the regeneration of new bone and bone. To fill bone defects, a large number of different materials are already being used. For example, fully synthetic bone substitutes based on calcium phosphate or transplants of natural bone or bone fragments are used.
  • the material which is used for filling up the bone defects allows and supports the rebuilding of the body's own bones, so that after some time the external material can be replaced more or less completely by body material. Therefore, the ability of the filler to be absorbed by the body plays a major role.
  • Previously used bones, bone splits or inorganic Knochener ⁇ set materials have the disadvantage that the absorption takes a very long time.
  • the absorption of the inorganic portion of the filler is the speed-determining step.
  • filling materials used hitherto often have the disadvantage that the formation and regeneration of the body's own bone or cartilage material is not or only insufficiently stimulated or promoted.
  • the invention therefore has as its object to provide a material for filling bone defects, which essentially corresponds to the natural bone composition, but nevertheless is degradable well and at relatively high speed.
  • this material should have osteoconductive properties, ie provide a support structure for the reconstruction of endogenous bones.
  • this filler should have osteoinductive properties, ie properties that promote and support the formation of the body's own bone or cartilage tissue in a special way.
  • Roth ⁇ there should be the possibility that the filler identifies properties that are beneficial in any other way.
  • This object is achieved by a material as described in claim 1 be ⁇ . Preferred embodiments of this material are set forth in the dependent claims. Claim 13 relates to a suitable kit for providing such a bioresorbable material. By reference, the wording of all claims is made the content of the description.
  • the material for filling bone defects is a bioabsorbable material which comprises a demineralized xenogenic bone material and at least one additive, active ingredient and / or extract.
  • the demineralized bone material is a so-called bone matrix, from which the inorganic portion (minerals) is almost completely removed except for traces.
  • DBM demineralized bone matrix
  • the bone material consists essentially only of the organic matrix, but which largely corresponds to the natural composition of the bone.
  • a natural bone consists of inorganic components, mainly hydroxyapatite. In addition to about 10% of water, the remaining 20% of organic constituents are formed, these being mainly collagen. To a small extent, non-collagenous proteins, in particular osteocalcin, osteonectin and osteopontin, cytokines, growth factors, proteoglycans and fats are present.
  • the demineralized bone material thus essentially represents a mixture of various proteins (proteins) whose main component is collagen.
  • proteins proteins
  • these are mainly collagen type I.
  • Conventionally already used collagen sponges are generally produced from skin or tendons. They also consist at least partly of collagen type I, which may be present in the native state. For these products, however, the "natural environment" is destroyed. disturbs.
  • the proteins of the demineralized bone material used according to the invention are in a natural state.
  • the environment and composition of the proteins of the bone material are not artificially brought into a new form.
  • the natural network of collagen fibers and / or fibrils is therefore still preserved.
  • This causes the demineralized bone material in its composition and structure comes very close to natural bone and thus has ideal osteoconductive properties.
  • the demineralized bone material is rapidly degraded as an organic matrix in the body and thus already allows the formation of endogenous bone material in a special way and promotes.
  • the demineralized bone material used according to the invention is xenogenic material, ie bone material of a foreign origin. When filling bone defects in humans, therefore, no human bone (allogeneic material) is used as the source of the bone material. This has the advantage that the risk of transmissible (pathogenic) pathogens is significantly reduced. Bone material of xenogeneic origin generally has no or only a few pathogens that could be dangerous to humans. Xenogenic material is thus less risky than allogeneic material since human pathogens are relatively selenium in xenogeneic material.
  • the demineralized bone material is particularly advantageously suitable as a carrier for additives, active substances, extracts or, for example, also for cells which are likewise to be understood hereunder.
  • the properties of the material can be defined and adjusted by such substances so as to adapt the material according to the invention to the respective applications.
  • additives agents or extracts are a variety of substances in question.
  • biologically active additives and / or active substances or biological extracts are particularly preferred.
  • Der ⁇ like substances may be advantageous for product protection by z. B. prevent microbial degradation.
  • physical properties of the bioresorbable material can also be specifically modulated by additives. The release of active ingredients from the material can be influenced by other additives.
  • Suitable active substances are in particular those substances which are locally effective and effect their effect in the immediate vicinity of the bone defect.
  • systemically active substances can also be introduced into the body through the bioresorbable material. This depends on the particular application and the defect to be treated.
  • a binder and / or a crosslinking agent may advantageously be used as additive or as active substance, whereby the modification possibilities of the bioresorbable material can be widely used. be increased.
  • the stability and / or the porosity of the material can be influenced.
  • binders influences the porosity. For example, when particles are merely agitated with the binder, porosity tends to be greatly reduced. If this is not desired, depending on the application, superficial conditioning of the individual particles is advantageous, ie, superficial treatment of the individual particles with binder.
  • amphoteric agents and / or salts the hydrophilicity of the bioresorbable material can be influenced.
  • Biological substances are particularly preferred as amphoteric agents.
  • a reconstitution agent can be provided as additive. This is particularly advantageous if the bioresorbable material is in dried form and is remoistened before use.
  • the rewetting of dried biopolymers can be problematic since the biopolymers or the bioresorbable material may no longer have the desired properties after rewetting.
  • substances which are advantageous in the case of restitution and which, after addition of, for example, water or physiological saline solution, give the desired consistency and the desired properties of the bioresorbable material.
  • substances which generally influence the consistency of the bioresorbable material for this purpose, substances which can be used to set the viscosity in the first place come into question.
  • salts are suitable, in particular salts of anionic or cationic polymers and / or biopolymers.
  • bioresorbable material itself can be protected. the, in particular against bacterial decomposition.
  • bioresorbable material can hereby be provided with specific functions which unfold advantageous action in the body of the patient. This can be done, for example, for therapeutic reasons and / or to support bone healing and / or regeneration.
  • the bone and / or cartilage renewal can be improved or promoted, thereby speeding up the integration and healing processes in the patient.
  • the bioresorbable material itself already has osteoinductive properties.
  • Suitable growth factors are, for example, BMP (bovine morphogenetic protein), in particular BMP-2, BMP-7 and / or BMP-4, and IGF (insuline-like growth factor), in particular IGF-I, and TGF (transforming growth factor) , in particular TGF-ßl.
  • the bioresorbable material can be equipped with one or more cytostatic agents. This is particularly advantageous in the case of cancerous changes in the region of the bone defect and / or of the surrounding tissue.
  • radioactive material which is likewise suitable for killing de-entrant tissue, especially in local areas.
  • antibiotics as the active ingredient is preferred. On the one hand, this can avoid defense reactions in the body, on the other hand, product protection of the bioresorbable material can also be achieved by this means.
  • the use of antibodies in this context may be useful, especially for therapeutic reasons.
  • the bioresorbable material may be provided with an extract, in particular a biological extract.
  • an extract may contain, for example, a combination of various active substances which may be biologically active.
  • Such an extract is preferably obtained from biological material.
  • it can be an extract of demineralized bone material which contains various substances, especially biologically active substances, which are very active with regard to bone or cartilage formation.
  • Such an extract is sold as a product by the applicant under the trade name "COLLOSS.”
  • such an extract can be used in combination with other active substances, in particular with other biologically active substances.
  • the additives, active ingredients and / or extracts can be mixed with the bioabsorbable material, which is present for example from powder, and thus made available for use.
  • the bioabsorbable material which is present for example from powder, and thus made available for use.
  • demineralized and, in particular, degreased and conditioned bone material may advantageously be coated with an extract, in particular with the "COLLOSS” mentioned, in particular moldings are suitable for such a coating for the use of "COLLOSS” according to the cited patent applications that the final step in the preparation of the extract is used before lyophilization
  • a coating of this kind can be used to produce a bioabsorbable material which is both osteoconductive and osteoinductive
  • the pore structure is optimized not only between the individual particles but also within the particles, whereby an interconnecting porosity is provided within the particles
  • the coating of the material optimally distributes the extract with its active substances in the bone defect to be filled in.
  • the stability of the particles prevents collapse of the material used
  • the substances contained in the substance are advantageously presented on the inner and / or outer surface of the particles, so that these substances are available to the body, in particular to the body's own cells.
  • This accessibility of the active substances is markedly improved, for example, in comparison with autologous bone as filling material.
  • the addition of the substances can take place before or after drying the material.
  • either the ready-to-bioresorbable material with the additives for the application can be provided, or the user is given the opportunity to coat the material himself or to coat the other substances.
  • This can be done by offering a kit containing all the essential components.
  • their stability should be taken into account with respect to the production conditions and the sterilization process. In the event that the user provides the product itself with appropriate substances, this advantageously must not be taken into account.
  • bioresorbable material By providing them with additives, active ingredients and / or extracts, on the one hand outer surfaces of the bioresorbable material and on the other hand additionally or alternatively cavities or inner spaces of the bioresorbable material may be provided with the substances. It is particularly preferred if active substances are used in such a way that a controlled release is made possible. This can be achieved, for example, by equipping or modifying the interior spaces and / or pores of the bioresorbable material with the active substances, so that the active ingredient is bound and then released in a retarded manner.
  • the bone material used is degreased.
  • the fat content of the natural bone composition can be reduced or almost completely removed.
  • Such degreasing may be performed before or after demineralization of the bone material.
  • the processes of demineralization and degreasing effectively also inactivate the transmissible pathogens that may be present in the xenogeneic source material.
  • it is ensured that the resulting material has osteoinductive properties, ie is able to promote ectopic bone formation.
  • this material according to the invention is at the same time osteoconductive and in particular osteoinductive.
  • the material can be produced by milling bone, demineralizing, in particular with acid, and further working up the insoluble fraction of the demineralized material to establish a tissue-compatible environment.
  • the material can be degreased at any time prior to further processing to adjust the tissue-compatible environment with preferably organic solvent.
  • this removal takes place before or after demineralisation with acid.
  • Milling of the bone to bone meal is carried out according to methods familiar to the person skilled in the art. It is particularly advantageous that the resulting bone meal has a particle size range of about 30 to about 3,000 ⁇ m, preferably about 100 to about 2,000 ⁇ m. In order to set a suitable particle size, the bone can be ground and / or sieved accordingly.
  • the degreasing is preferably carried out with the aid of ethanol and / or acetone.
  • hydrochloric acid is preferably used for demineralization (decalcification).
  • the further work-up of the material is advantageous in order to be able to provide a tissue-friendly product which is well worn by the patient.
  • conditioning process chemicals are mainly removed. This can advantageously be carried out in such a way that the resulting particles are washed free of chemicals and neutral with water, saline water and / or buffer.
  • the resulting moist material can be adjusted in dry matter content. It can be moist or dry.
  • all animals with skeletal system come into question as source for the xenogenic bone material.
  • Cow, horse or pig, ie bovine, equine or porcine starting material are particularly preferred.
  • all types of bones of the skeleton can be used, in particular long bones, above all the cortex of the long bones.
  • the bioresorbable material is present as a powder for the application.
  • a powder is to be understood as meaning a material in which the bone meal particles are essentially present next to each other in a single piece.
  • the bioresorbable material is present as granules for the application.
  • a granulate consists of granules.
  • Such a granulate is formed by storing several bone meal particles together to form a superordinate structure. These may be, for example, spherical shapes.
  • a granule is therefore in principle a small shaped body, which may be round or rounded.
  • Granules can be produced, for example, by thermal and / or pressing pressure treatment from bone meal, that is to say from a powder. Under pressing pressure here is a pressure to be understood, which is built up within a press.
  • the particle size of the bone meal or of the powder or of the granules can be adjusted to a defined size range. The particle size distribution can be chosen differently for different applications.
  • the material is present as a shaped body.
  • Shaped bodies are aggregates of bone meal particles with a defined shape, for example blocks, cuboids, slices or the like. It can create moldings of any shape.
  • the shaped bodies can be adapted to the defects to be filled out by mechanical processing by the user Granules and shaped bodies essentially differ only in size
  • a shaped body can also be produced by thermal and / or pressing pressure treatment from powder or granules ,
  • bioresorbable material as a powder, as a granulate or as a shaped body depend essentially on the respective application, the method of treatment and the stability to be required.
  • powder or granules are especially powder or granules.
  • a particular advantage of the bioresorbable material according to the invention lies in its porosity.
  • the porosity By the expression of the porosity, the vulnerability is influenced by the body's own factors, especially by cells. In this way, therefore, the degradability in the body is influenced be ⁇ .
  • a majority of the pores of the material is in the size range over 100 microns. These pores are thus optimally suitable for growing cells. This promotes the integration of the filling material in the body as well as its degradation or absorption.
  • Particularly advantageous are interconnecting, ie substantially continuous, pores.
  • the pores in the materials are essentially produced by the particle size distribution of the bone meal. They differ in the bed, so in powder or granules, and in such moldings, which are produced with minimal pressure, only insignificantly.
  • the porosity of the granules is also determined by the treatment conditions for the preparation of the granules, especially temperature and time.
  • the treatment conditions for the preparation of the granules especially temperature and time.
  • the porosity of shaped bodies is determined on the one hand by the grain size of the starting material and on the other hand by the pressing pressure and the other conditions of manufacture of the shaped body, above all temperature and time.
  • the stability especially of the granules and moldings can also be influenced by the production conditions. Important factors here are the particle size of the starting material, the pressure in particular in the production of moldings and the other conditions of manufacture, especially temperature and time.
  • the material is dried or is in dry form, in particular if it is present as a shaped body.
  • both a dry and a moist form of delivery may be preferred.
  • the material finally used for the application is dried or is in dry form.
  • the presence in dry form is advantageous in particular with regard to stability and durability, since the product moisture generally affects the stability and durability unfavorably.
  • the material is vor ⁇ preferably as a wet mass. As a result, an agglomeration and thus a substantially stable intermediate form is achieved, which can be further stabilized by further treatment.
  • Drying can be carried out, for example, by lyophilization and / or by air drying.
  • the drying can be supported by Temperatur ⁇ application and / or vacuum.
  • the drying can be carried out in wide temperature ranges. It should be noted that the type and conditions of drying can influence the properties of the bioresorbable material. If, for example, particularly osteoinductive materials are to be produced, it should be dried in a gentle manner. For this purpose, for example, a demineralized and degreased bone material at low temperatures under Vacuum produced.
  • a free-flowing powder can be produced.
  • a suitable device for example a granulating plate
  • subsequent drying it is possible to provide a granulate with different particle sizes.
  • By pressing before drying it is possible to produce any desired shaped bodies.
  • a lyophilized material often differ from the properties of a temperature treated material.
  • a shaped body produced from lyophilized material has a relatively low stability, so that the addition of binders for the production of the shaped body can be advantageous.
  • the material is sterilized or is present in sterilized form. Sterilization can be carried out using various customary methods.
  • the bioresorbable material can be irradiated, in particular with radioactive rays, and / or gassed, for example with ethylene oxide. Since the bioresorbable material is provided with additives, active ingredients and / or extracts and the material itself also has osteoinuctive properties, it is generally to be considered that the sterilization can influence the effectiveness of the substances used. Very particular preference is given to aseptic preparation of the bioresorbable material.
  • the problems of sterilization can be circumvented, which can have a detrimental effect, for example, on the efficacy of the additives, active substances or extracts or on the osteoinductive properties of the material itself.
  • aseptic preparation or processing of the demineralized bone material and / or use of sterile-filtered solutions for example sterile-filtered antibiotic solutions, are preferred.
  • a shaped article can be prepared aseptically and, after pressing / drying, treated with a sterile-filtered gentamycin solution before it is dried again, for example by vacuum drying or lyophilization.
  • the bioresorbable material is present in packaged form. It is particularly preferred if the material is packed sterile. Within such a package, the material can be shipped and / or stored. During use, the material can be removed from the packaging in a simple manner and used. In order to achieve sterility, provision may be made, for example, for the body to be sterilized before packaging or else inside the packaging, for example by irradiation. Suitable materials for packaging are various materials, for example plastic casings or the like. Also suitable as packaging are, inter alia, special syringes in which the piston does not end or ends only in a slight taper.
  • the moist bioresorbable material which can be adjusted to a defined dry matter content, can be filled and thus made available to the user in a practical manner.
  • additives and / or active substances can be added to the syringes before the actual filling.
  • the invention comprises a kit for providing a bioabsorbable material for filling bone defects as described above.
  • This kit comprises at least one demineralized xenogenic bone material and preferably at least one additive, active substance and / or an extract.
  • the user has the option of providing the demineralized xenogenic bone material which is used to fill bone defects with one or more active substances which may be adapted to the particular application. Therefore, various substances can be provided as additives, active ingredients and / or extracts in the kit, so that the user can select the respective suitable substance or substances.
  • the separate provision of demineralized xenogenic bone material and the other substances can enable increased storage stability.
  • the kit may also contain, for example, components which are suitable for rewetting or reconstitution of the material present in dry form in this case. These are, for example, sterile water, physiological saline or suitable buffers. Furthermore, such a kit can also contain other auxiliaries, for example tools, which can be used on the patient during use.
  • a demineralized, degreased and conditioned bone matrix having a particle size below 2,000 ⁇ m used for the production of a shaped body having a diameter of 0.8 mm and a height of 0.5 mm.
  • the moist matrix is placed in a press which consists of a tube with a diameter of 0.8 cm and a piston. By compressing a moist shaped body of about 0.5 cm height is generated. This is followed by drying under aseptic conditions in vacuo at temperatures up to 60 ° C., preferably up to 45 ° C., for 4 to 60 hours.
  • a sterile product is optionally obtained after sterilization with suitable methods, in particular with irradiation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne une matière biorésorbable destinée à remplir les défauts osseux. Cette matière contient une matière osseuse xénogène déminéralisée ainsi qu'au moins un adjuvant, un principe actif et/ou un extrait. Cet adjuvant et/ou ce principe actif est avantageusement une substance biologiquement active et/ou l'extrait est avantageusement un extrait biologique.
PCT/EP2005/007908 2004-07-22 2005-07-20 Matiere bioresorbable destinee a remplir les defauts osseux Ceased WO2006010547A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004036881.3 2004-07-22
DE200410036881 DE102004036881A1 (de) 2004-07-22 2004-07-22 Bioresorbierbares Material zur Füllung von Knochendefekten

Publications (2)

Publication Number Publication Date
WO2006010547A2 true WO2006010547A2 (fr) 2006-02-02
WO2006010547A3 WO2006010547A3 (fr) 2006-04-06

Family

ID=35530825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007908 Ceased WO2006010547A2 (fr) 2004-07-22 2005-07-20 Matiere bioresorbable destinee a remplir les defauts osseux

Country Status (2)

Country Link
DE (1) DE102004036881A1 (fr)
WO (1) WO2006010547A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107122A3 (fr) * 2007-03-08 2009-03-12 Sbf Synthetic Bone Factory Gmb Composition pour traiter des défauts osseux et/ou cartilagineux

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034420A1 (de) * 2004-12-23 2006-07-06 Ossacur Ag Gelartiges Material zur Füllung von Knochen- und/oder Knorpeldefekten
DE102006011211A1 (de) * 2006-03-02 2007-09-06 Ossacur Ag Material zur Behandlung von Knochen- und/oder Knorpeldefekten
US8114428B2 (en) 2007-03-08 2012-02-14 Sbf Synthetic Bone Factory Gmbh Methods for manufacturing a composition for treating bone and/or cartilage defects
CA2686439A1 (fr) * 2007-09-10 2009-03-19 Sbf Synthetic Bone Factory Gmbh Composant et dispositif de traitement des deficiences osseuses et cartilagineuses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627853A (en) * 1985-05-29 1986-12-09 American Hospital Supply Corporation Method of producing prostheses for replacement of articular cartilage and prostheses so produced
US4678470A (en) * 1985-05-29 1987-07-07 American Hospital Supply Corporation Bone-grafting material
US4975526A (en) * 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US5250302A (en) * 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
US5061286A (en) * 1989-08-18 1991-10-29 Osteotech, Inc. Osteoprosthetic implant
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
EP0483944B1 (fr) * 1990-10-31 1995-07-05 El Gendler Membranes flexibles produites à partir d'une matrice osseuse organique pour la réparation et reconstruction du squelette
US5507813A (en) * 1993-12-09 1996-04-16 Osteotech, Inc. Shaped materials derived from elongate bone particles
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
US6290718B1 (en) * 1998-02-02 2001-09-18 Regeneration Technologies, Inc. Luminal graft, stent or conduit made of cortical bone
WO1999047080A1 (fr) * 1998-03-16 1999-09-23 Crosscart, Inc. Xenogreffes osseuses
US6340477B1 (en) * 2000-04-27 2002-01-22 Lifenet Bone matrix composition and methods for making and using same
DE10026306A1 (de) * 2000-05-26 2001-11-29 Tutogen Medical Gmbh Transplantat

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107122A3 (fr) * 2007-03-08 2009-03-12 Sbf Synthetic Bone Factory Gmb Composition pour traiter des défauts osseux et/ou cartilagineux

Also Published As

Publication number Publication date
DE102004036881A1 (de) 2006-02-16
WO2006010547A3 (fr) 2006-04-06

Similar Documents

Publication Publication Date Title
DE19953771C1 (de) Resorbierbares Knochen-Implantatmaterial sowie Verfahren zur Herstellung desselben
DE69735625T2 (de) Verfahren zur herstellung flexibler schichten aus deminaralisierten,länglichen knochenpartikeln
DE69430069T2 (de) Förmige materialien auf der basis von länglichen knochenteilchen und verfahren zu ihrer herstellung
DE60020526T2 (de) Osteogene pastenzusammensetzungen und ihre verwendung
DE69633197T2 (de) Osteogene vorrichtungen und methode zur herstellung derselben
DE69632829T2 (de) Knochentransplantatmatrix
DE60302224T2 (de) Poröses und bioabbaubares implantatmaterial und verfahren zu seiner herstellung
DE69118505T2 (de) Knochenbildende Zusammensetzung und ein diese enthaltendes Implantat
DE60026586T2 (de) Zellulare matrix
DE60006356T2 (de) Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung
DE69621595T2 (de) Knochentransplantat-verbindungen
DE69626205T2 (de) Terminal-sterilisierte osteogene vorrichtungen und ihre herstellung
DE3588120T2 (de) Kollagenknochenersatzmaterial
DE69024970T2 (de) Verfahren zur herstellung eines werkstoffes für osteoplastik aus natürlichem knochengewebe sowie aus solchem verfahren gewonnenes material
Parizi et al. Human platelet rich plasma plus Persian Gulf coral effects on experimental bone healing in rabbit model: radiological, histological, macroscopical and biomechanical evaluation
DE60016614T2 (de) Zusammensetzungen zur abgabe osteogener proteine
WO2003092760A1 (fr) Composites structures en tant que matrice pour la production de tissus osseux par ingenierie genetique
EP0925076B1 (fr) Procede de production d'un implant compose d'un materiau support resorbable renfermant une pharmaceutice, un antibiotique, un cytostatique ou une hormone
EP1835945A2 (fr) Matiere de type gel destinee a remplir des defauts des os et / ou du cartilage
WO2011018520A2 (fr) Procédé de production d'un matériau composite biocompatible et biodégradable, matériau composite ainsi obtenu et son utilisation comme produit médical
WO2006010507A2 (fr) Substance bioresorbable pour le remplissage de defauts osseux
WO2006010547A2 (fr) Matiere bioresorbable destinee a remplir les defauts osseux
DE112016001386B4 (de) Kohlenstoffpartikel und Komposite derselben für die Regeneration von Skelettmuskelgewebe und Weichgewebe
EP1263929A2 (fr) Copeaux osseux artificiels, procedes permettant de les produire et utilisation
DE60025278T2 (de) Volumenstabile osteoinduktive / osteokonduktive zusammensetzungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase